Phaseline

Targets › TOPO1

TOPO1: drug programs, companies and trials

19 programs from 17 companies in 28 trials: 13 Phase 2, 11 Phase 3, 4 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on TOPO1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Assistance Publique - Hôpitaux de ParisModified FOLFIRINOX
Combination chemotherapy: topoisomerase I inhibitor (irinotecan), topoisomerase II inhibit
TOPO1, TOPO2A, MTHFR, TYMSPhase 3Rectal CancerDec 2026
Sun Yat-sen UniversitymFOLFOXIRI
Multi-drug chemotherapy regimen: oxaliplatin (platinum-based DNA crosslinker), irinotecan
TOPO1, TOPO2A, ERCC1Phase 3Colon Cancer Stage IIDec 2026
GenmabRina-S
Topoisomerase 1 inhibitor conjugate (SN-38 payload on anti-TROP-2 antibody)
TOPO1Phase 3Platinum-resistant Ovarian Cancer; Ovarian Cancer; Endometrial Cancer; Platinum-Sensitive Ovarian Cancer …Sep 2027
Dominik Paul ModestmFOLFOXIRI
Combination chemotherapy: topoisomerase I inhibitor (irinotecan), topoisomerase II inhibit
TOPO1, TOPO2APhase 3Colorectal CancerNov 2027
Seoul National University HospitalmFOLFIRINOX (preoperative)
Multi-agent chemotherapy combining irinotecan (topoisomerase I inhibitor), fluorouracil (t
TOPO1, DHFR, TYMSPhase 3Resectable Pancreatic CancerDec 2027
Fudan UniversitymFOLFIRINOX adjuvant chemotherapy
Multi-agent chemotherapy: oxaliplatin (platinum agent), irinotecan (topoisomerase I inhibi
DHFR, TYMS, TOPO1, SLC22A16Phase 3High-risk Stage II Colorectal CancerJun 2028
National Cancer Center Hospital EastCAPOXIRI
Combination chemotherapy: capecitabine (5-FU prodrug), oxaliplatin (platinum agent), and i
DPYD, TOPO1, XRCC1Phase 3Locally Advanced Rectal CancerDec 2029
Rutgers, The State University of New JerseysFOLFOXIRI (alternating FOLFOX and FOLFIRI)
Fluorouracil-based chemotherapy combining FOLFOX (5-fluorouracil, leucovorin, oxaliplatin)
DHFR, TYMS, TOPO1Phase 2Gastro-Intestinal CancerFeb 2027
Centre Hospitalier Universitaire DijonFOLFOXIRI Protocol (modified FOLFIRINOX)
Combination chemotherapy: irinotecan (TOPO1 inhibitor) + oxaliplatin (TOPO2 inhibitor) + f
TOPO1, TOPO2, TYMSPhase 2Locally Advanced or Metastatic Small Bowel Adenocarcinoma; Neuroendocrine CarcinomaFeb 2027
Seoul National University Bundang HospitalmFOLFOX/mFOLFIRI
Combination of fluorouracil with oxaliplatin and irinotecan
TOPO1, TOPO2APhase 2Biliary Cancer MetastaticApr 2027
Peking Union Medical College HospitalNALIRIFOX
Combination chemotherapy (liposomal irinotecan, oxaliplatin, leucovorin); irinotecan is a
TOPO1Phase 2Locally Advanced Pancreatic CancerMay 2027
Fudan UniversitymFOLFIRINOX plus IMRT
Multi-drug chemotherapy regimen (5-fluorouracil, folinic acid, irinotecan, oxaliplatin) co
TOPO1, DPYD, TYMS, DHFRPhase 2Pancreatic Adenocarcinoma; Pancreatic CancerMar 2028
Sun Yat-sen UniversityNALIRIFOX
Combination chemotherapy regimen containing liposomal irinotecan (TOP1 inhibitor), oxalipl
TOP1, TOPO1Phase 2Rectal CancersJun 2028
Institut du Cancer de Montpellier - Val d'Aurellemodified FOLFIRINOX regimen
Combination chemotherapy: irinotecan (topoisomerase I inhibitor), oxaliplatin (platinum cr
TOPO1, TOPO2A, ERCC1Phase 2Locally Advanced Malignant NeoplasmSep 2029
Catharina Ziekenhuis EindhovenFOLFOXIRI Protocol
Combination chemotherapy: oxaliplatin (platinum-based alkylating agent), irinotecan (topoi
TOPO1Phase 2Rectal CancerAug 2031
Hospital Universitario Doctor Pesetmodified TPF
Modified docetaxel-cisplatin-fluorouracil chemotherapy combination
TOPO2A, TOPO1Phase 2Locally Advanced Head and Neck Squamous Cell Carcinoma–
University of Colorado, DenverNALIRIFOX
Combination of liposomal irinotecan (topoisomerase I inhibitor), 5-fluorouracil (thymidyla
TOPO1, TOPO2A, TYMSPhase 1Pancreatic Ductal Adenocarcinoma (PDAC)Jul 2028
The Methodist Hospital Research InstituteNALIRIFOX
Topoisomerase I inhibitor (liposomal irinotecan) combined with fluoropyrimidine and platin
TOPO1Phase 1Advanced Small Intestine CancerSep 2028
SN BioScienceSNB-101
Nanoparticle formulation of SN-38 (topoisomerase I inhibitor)
TOPO1Phase 1Patient is Not Suitable for Complete Surgical Resection With a Cytologically or Histologically Confirmed Small Cell Lung Cancer(SCLC)Dec 2028

Conditions

Platinum-resistant Ovarian Cancer (2) Rectal Cancer (2) Locally Advanced Head and Neck Squamous Cell Carcinoma (1) Locally Advanced or Metastatic Small Bowel Adenocarcinoma (1) Neuroendocrine Carcinoma (1) Locally Advanced Rectal Cancer (1) Ovarian Cancer (1) Endometrial Cancer (1) Platinum-Sensitive Ovarian Cancer (1) Non-small Cell Lung Cancer (NSCLC) (1) Gastrointestinal Cancers (1) High Grade Epithelial Ovarian Cancer (1)

Modalities

small molecule (15), antibody (2), mixed (1)

Companies

Sun Yat-sen University (2) Fudan University (2) Hospital Universitario Doctor Peset (1) Centre Hospitalier Universitaire Dijon (1) National Cancer Center Hospital East (1) Genmab (1) Assistance Publique - Hôpitaux de Paris (1) Rutgers, The State University of New Jersey (1) Seoul National University Bundang Hospital (1) University of Colorado, Denver (1) Peking Union Medical College Hospital (1) Seoul National University Hospital (1) SN BioScience (1) The Methodist Hospital Research Institute (1) Catharina Ziekenhuis Eindhoven (1) Dominik Paul Modest (1) Institut du Cancer de Montpellier - Val d'Aurelle (1)

Related targets

TOPO2A (7) TYMS (7) DHFR (4) DPYD (2) ERCC1 (2) TOPO2 (1) XRCC1 (1) TOP1 (1) MTHFR (1) SLC22A16 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.